BioCryst Pharmaceuticals (BCRX) Raised to Strong-Buy at ValuEngine

ValuEngine upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a buy rating to a strong-buy rating in a report issued on Friday morning.

A number of other research analysts also recently issued reports on the company. HC Wainwright reaffirmed a buy rating and set a $13.00 price target on shares of BioCryst Pharmaceuticals in a report on Monday, August 13th. They noted that the move was a valuation call. JMP Securities increased their target price on BioCryst Pharmaceuticals from $12.00 to $16.00 and gave the company an outperform rating in a report on Wednesday, September 5th. JPMorgan Chase & Co. began coverage on BioCryst Pharmaceuticals in a report on Wednesday, August 8th. They issued an overweight rating and a $9.00 target price on the stock. Bank of America raised BioCryst Pharmaceuticals from an underperform rating to a neutral rating in a report on Tuesday, July 17th. Finally, BidaskClub downgraded BioCryst Pharmaceuticals from a buy rating to a hold rating in a report on Saturday, September 15th. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company. BioCryst Pharmaceuticals has a consensus rating of Buy and a consensus target price of $9.89.

Shares of NASDAQ:BCRX traded up $0.38 during midday trading on Friday, reaching $7.01. 514,199 shares of the company’s stock traded hands, compared to its average volume of 880,043. The company has a market cap of $834.59 million, a P/E ratio of -8.99 and a beta of 1.64. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.25 and a quick ratio of 1.25. BioCryst Pharmaceuticals has a one year low of $4.12 and a one year high of $8.13.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.05. The firm had revenue of $12.49 million for the quarter, compared to the consensus estimate of $3.80 million. BioCryst Pharmaceuticals had a negative return on equity of 107.85% and a negative net margin of 270.95%. On average, sell-side analysts anticipate that BioCryst Pharmaceuticals will post -0.86 earnings per share for the current year.

In other BioCryst Pharmaceuticals news, CMO William P. Sheridan sold 62,500 shares of the stock in a transaction dated Thursday, August 9th. The stock was sold at an average price of $7.03, for a total value of $439,375.00. Following the transaction, the chief marketing officer now owns 85,713 shares of the company’s stock, valued at $602,562.39. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Thomas R. Staab II sold 9,850 shares of the stock in a transaction dated Wednesday, October 3rd. The shares were sold at an average price of $7.24, for a total value of $71,314.00. Following the completion of the transaction, the insider now directly owns 140,633 shares in the company, valued at approximately $1,018,182.92. The disclosure for this sale can be found here. 5.21% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the business. Janus Henderson Group PLC increased its position in BioCryst Pharmaceuticals by 45.0% in the second quarter. Janus Henderson Group PLC now owns 11,096,183 shares of the biotechnology company’s stock worth $63,581,000 after buying an additional 3,441,498 shares in the last quarter. BlackRock Inc. increased its position in BioCryst Pharmaceuticals by 3.8% in the second quarter. BlackRock Inc. now owns 7,755,951 shares of the biotechnology company’s stock worth $44,442,000 after buying an additional 281,532 shares in the last quarter. VHCP Management II LLC increased its position in BioCryst Pharmaceuticals by 11.0% in the second quarter. VHCP Management II LLC now owns 2,464,241 shares of the biotechnology company’s stock worth $14,120,000 after buying an additional 243,270 shares in the last quarter. UBS Group AG increased its position in BioCryst Pharmaceuticals by 190.7% in the first quarter. UBS Group AG now owns 291,379 shares of the biotechnology company’s stock worth $1,390,000 after buying an additional 191,157 shares in the last quarter. Finally, Allianz Asset Management GmbH increased its position in BioCryst Pharmaceuticals by 40.5% in the first quarter. Allianz Asset Management GmbH now owns 231,761 shares of the biotechnology company’s stock worth $1,105,000 after buying an additional 66,783 shares in the last quarter. 80.23% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.

See Also: How analysts view the yield curve

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply